Clinical trialNCT00099489CompletedPhase 2Interventional

Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

SponsorBiogenEnrollment67Chronic Inflammatory Demyelinating Polyradiculoneuropathy

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine whether AVONEX (Interferon Beta-1a), when compared to placebo, reduces the total dose of IVIg that is administered after Visit 5 and through Visit 9 (Week 32, End of Study).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Allan Ropper, MD
Tufts University School of Medicine, St. Elizabeth's Medical Center
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Kate Dawson, MD
Biogen
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Liverpool Hospital
Liverpool, New South Wales, Australia
Institute of Clinical Neurosciences
Sydney, New South Wales, Australia
St. Vincent'S Hospital
Fitzroy, Victoria, Australia
Royal Melbourne Hospital
Parkville, Victoria, Australia

Canada

London Health Sciences Center
London, Ontario, Canada
Montreal Neurological Hospital
Montreal, Quebec, Canada

United Kingdom

Guy'S Hospital/dept. of Neuroimmunology
London, United Kingdom

United States

Phoenix Neurological Associates, Ltd.
Phoenix, Arizona, United States
Neuromuscular Research Center
Scottsdale, Arizona, United States
University of Florida, Jacksonville
Jacksonville, Florida, United States
University of Miami
Miami, Florida, United States
University of Kansas
Kansas City, Kansas, United States
Louisiana State University
New Orleans, Louisiana, United States
Harvard University/mgh
Boston, Massachusetts, United States
Tufts University/ St. Elizabeths
Boston, Massachusetts, United States
University of Minnesota
Minneapolis, Minnesota, United States
Weill Medical College of Cornell University
New York, New York, United States
Raleigh Neurology Associates
Raleigh, North Carolina, United States
University of Texas Southwestern
Dallas, Texas, United States
University of Utah
Salt Lake City, Utah, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Interferon beta-1a →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 29 Feb 2004
Primary completion: 28 Feb 2006
Completion: 28 Feb 2006
Last update posted: 5 Mar 2010
Registered enrollment: 67
Registry id: NCT00099489

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.